Every Form 4 that Processa Pharmaceuticals, Inc. (PCSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals director Neal James R reported an open-market purchase of the company’s Common Stock. On March 31, 2026, he bought 789 shares at a price of $2.535 per share, bringing his direct ownership to 818 shares after the transaction, indicating a small, routine insider buy.
Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share. After this trade, he directly holds 10,562 shares and has additional indirect holdings through the Young-Plaisance Revocable Trust, family entities, and CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. He bought 2,324 shares of Common Stock at a price of $2.535 per share on March 31, 2026, and now directly holds 2,324 shares following this transaction.
Processa Pharmaceuticals director Geraldine Pannu reported an open-market purchase of Common Stock. On March 31, 2026, she bought 2,072 shares at $2.535 per share, bringing her direct holdings to 2,188 shares. This was a straightforward open-market buy with no derivatives involved.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock. On March 31, 2026, he made an open-market purchase of 2,136 shares of Processa common stock at $2.535 per share.
Following this transaction, Ng directly holds 3,649 common shares. He also has indirect ownership of 3,488 shares through an account labeled "George Ng IRRA FOB George Ng" and 800 shares through the "Ng Cha Family Trust," giving him a larger combined economic stake in PCSA.
Processa Pharmaceuticals, Inc. Chief Business & Strategy Officer Patrick Lin made an open-market purchase of 1,603 shares of common stock at $2.535 per share. Following this transaction, he directly holds 3,356 shares. In addition, 1,740 shares are held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy bought shares in the company. On the open market, she purchased 1,854 shares of common stock at $2.535 per share, increasing her direct holdings to 3,110 shares. She also has indirect ownership of 333 shares held by CorLyst, LLC.
Processa Pharmaceuticals’ Chief Development Officer, Bigora Sian, purchased common stock in the open market. On March 31, 2026, Sian bought 2,107 shares of Processa Pharmaceuticals common stock at $2.535 per share, increasing direct ownership to 3,711 shares. The filing also reports indirect ownership of 267 shares held through CorLyst, LLC.
Processa Pharmaceuticals director Baluch Khoso bought shares of the company in the open market. On this transaction date, he purchased 2,269 shares of Common Stock at an average price of $2.535 per share in an open-market purchase. Following this trade, he directly owns 2,325 Processa Pharmaceuticals common shares.
Processa Pharmaceuticals director and officer David Young, President of Research & Development, reported the vesting and distribution of restricted stock units into common stock on January 1, 2026. A total of 49 restricted stock units were converted at an exercise price of $0, resulting in 49 common shares acquired.
Following this transaction, Young holds 8,752 Processa common shares directly. He also has indirect beneficial ownership of common stock, including 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through family entities, and 742 shares through CorLyst, LLC. The filing describes the event as a distribution of vested restricted shares.
Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin reported a small equity transaction. On January 1, 2026, Lin acquired 193 shares of Common Stock at an exercise price of $0 through the conversion of a derivative security, described as a distribution of vested restricted shares.
Following this vesting-related transaction, Lin directly beneficially owned 1,753 shares of Common Stock. In addition, 1,740 shares were held indirectly through the Lin Family Trust Feb 4, 2024, reflecting his combined direct and indirect ownership position in Processa Pharmaceuticals.
Processa Pharmaceuticals, Inc. reported an equity award transaction by Chief Administrative Officer Wendy Guy. On January 1, 2026, 193 restricted stock units converted into 193 shares of common stock at a price of $0 per share, described as a distribution of vested restricted shares. Following the transaction, Guy beneficially owned 1,256 shares of common stock directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals Chief Development Officer Sian Bigora reported an equity award vesting and related share distribution. On January 1, 2026, 249 restricted stock units converted into 249 shares of common stock at an exercise price of $0, described as a distribution of vested restricted shares.
Following this transaction, Bigora beneficially owns 1,604 shares of Processa common stock directly and an additional 267 shares indirectly through CorLyst, LLC. The filing reflects compensation-related share delivery rather than an open‑market purchase or sale.